The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Hemoglobinopathies Market Research Report 2025
Synopsis
Hemoglobinopathy or Hemoglobinopathies is the medical term for a group of blood disorders and diseases that affect red blood cells. It can be a kind of genetic defect that results in abnormal structure of one of the globin chains of the hemoglobin molecule.
The global Hemoglobinopathies market was valued at US$ 274.5 million in 2023 and is anticipated to reach US$ 384.7 million by 2030, witnessing a CAGR of 4.5% during the forecast period 2024-2030.
According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
This report aims to provide a comprehensive presentation of the global market for Hemoglobinopathies, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hemoglobinopathies.
Report Scope
The Hemoglobinopathies market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Hemoglobinopathies market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Hemoglobinopathies companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Gamida Cell
Alnylam Pharmaceuticals
Sanofi
Sangamo Therapeutics Inc.
Global Blood Therapeutics
Bluebird Bio
Emmaus Life Sciences Inc.
Prolong Pharmaceuticals
Celgene Corporation
Segment by Type
Blood Transfusion
Iron Chelation Therapy
Bone Marrow Transplant
Others
Segment by Application
Blood Testing
Genetic Testing
Pre-Implantation Genetic Diagnosis (PGD)
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Hemoglobinopathies companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Hemoglobinopathy or Hemoglobinopathies is the medical term for a group of blood disorders and diseases that affect red blood cells. It can be a kind of genetic defect that results in abnormal structure of one of the globin chains of the hemoglobin molecule.
The global Hemoglobinopathies market was valued at US$ 274.5 million in 2023 and is anticipated to reach US$ 384.7 million by 2030, witnessing a CAGR of 4.5% during the forecast period 2024-2030.
According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
This report aims to provide a comprehensive presentation of the global market for Hemoglobinopathies, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hemoglobinopathies.
Report Scope
The Hemoglobinopathies market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Hemoglobinopathies market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Hemoglobinopathies companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Gamida Cell
Alnylam Pharmaceuticals
Sanofi
Sangamo Therapeutics Inc.
Global Blood Therapeutics
Bluebird Bio
Emmaus Life Sciences Inc.
Prolong Pharmaceuticals
Celgene Corporation
Segment by Type
Blood Transfusion
Iron Chelation Therapy
Bone Marrow Transplant
Others
Segment by Application
Blood Testing
Genetic Testing
Pre-Implantation Genetic Diagnosis (PGD)
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Hemoglobinopathies companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Hemoglobinopathies Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Blood Transfusion
1.2.3 Iron Chelation Therapy
1.2.4 Bone Marrow Transplant
1.2.5 Others
1.3 Market by Application
1.3.1 Global Hemoglobinopathies Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Blood Testing
1.3.3 Genetic Testing
1.3.4 Pre-Implantation Genetic Diagnosis (PGD)
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Hemoglobinopathies Market Perspective (2019-2030)
2.2 Hemoglobinopathies Growth Trends by Region
2.2.1 Global Hemoglobinopathies Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Hemoglobinopathies Historic Market Size by Region (2019-2024)
2.2.3 Hemoglobinopathies Forecasted Market Size by Region (2025-2030)
2.3 Hemoglobinopathies Market Dynamics
2.3.1 Hemoglobinopathies Industry Trends
2.3.2 Hemoglobinopathies Market Drivers
2.3.3 Hemoglobinopathies Market Challenges
2.3.4 Hemoglobinopathies Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Hemoglobinopathies Players by Revenue
3.1.1 Global Top Hemoglobinopathies Players by Revenue (2019-2024)
3.1.2 Global Hemoglobinopathies Revenue Market Share by Players (2019-2024)
3.2 Global Hemoglobinopathies Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Hemoglobinopathies Revenue
3.4 Global Hemoglobinopathies Market Concentration Ratio
3.4.1 Global Hemoglobinopathies Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Hemoglobinopathies Revenue in 2023
3.5 Hemoglobinopathies Key Players Head office and Area Served
3.6 Key Players Hemoglobinopathies Product Solution and Service
3.7 Date of Enter into Hemoglobinopathies Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Hemoglobinopathies Breakdown Data by Type
4.1 Global Hemoglobinopathies Historic Market Size by Type (2019-2024)
4.2 Global Hemoglobinopathies Forecasted Market Size by Type (2025-2030)
5 Hemoglobinopathies Breakdown Data by Application
5.1 Global Hemoglobinopathies Historic Market Size by Application (2019-2024)
5.2 Global Hemoglobinopathies Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Hemoglobinopathies Market Size (2019-2030)
6.2 North America Hemoglobinopathies Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Hemoglobinopathies Market Size by Country (2019-2024)
6.4 North America Hemoglobinopathies Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Hemoglobinopathies Market Size (2019-2030)
7.2 Europe Hemoglobinopathies Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Hemoglobinopathies Market Size by Country (2019-2024)
7.4 Europe Hemoglobinopathies Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Hemoglobinopathies Market Size (2019-2030)
8.2 Asia-Pacific Hemoglobinopathies Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Hemoglobinopathies Market Size by Region (2019-2024)
8.4 Asia-Pacific Hemoglobinopathies Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Hemoglobinopathies Market Size (2019-2030)
9.2 Latin America Hemoglobinopathies Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Hemoglobinopathies Market Size by Country (2019-2024)
9.4 Latin America Hemoglobinopathies Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Hemoglobinopathies Market Size (2019-2030)
10.2 Middle East & Africa Hemoglobinopathies Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Hemoglobinopathies Market Size by Country (2019-2024)
10.4 Middle East & Africa Hemoglobinopathies Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Gamida Cell
11.1.1 Gamida Cell Company Detail
11.1.2 Gamida Cell Business Overview
11.1.3 Gamida Cell Hemoglobinopathies Introduction
11.1.4 Gamida Cell Revenue in Hemoglobinopathies Business (2019-2024)
11.1.5 Gamida Cell Recent Development
11.2 Alnylam Pharmaceuticals
11.2.1 Alnylam Pharmaceuticals Company Detail
11.2.2 Alnylam Pharmaceuticals Business Overview
11.2.3 Alnylam Pharmaceuticals Hemoglobinopathies Introduction
11.2.4 Alnylam Pharmaceuticals Revenue in Hemoglobinopathies Business (2019-2024)
11.2.5 Alnylam Pharmaceuticals Recent Development
11.3 Sanofi
11.3.1 Sanofi Company Detail
11.3.2 Sanofi Business Overview
11.3.3 Sanofi Hemoglobinopathies Introduction
11.3.4 Sanofi Revenue in Hemoglobinopathies Business (2019-2024)
11.3.5 Sanofi Recent Development
11.4 Sangamo Therapeutics Inc.
11.4.1 Sangamo Therapeutics Inc. Company Detail
11.4.2 Sangamo Therapeutics Inc. Business Overview
11.4.3 Sangamo Therapeutics Inc. Hemoglobinopathies Introduction
11.4.4 Sangamo Therapeutics Inc. Revenue in Hemoglobinopathies Business (2019-2024)
11.4.5 Sangamo Therapeutics Inc. Recent Development
11.5 Global Blood Therapeutics
11.5.1 Global Blood Therapeutics Company Detail
11.5.2 Global Blood Therapeutics Business Overview
11.5.3 Global Blood Therapeutics Hemoglobinopathies Introduction
11.5.4 Global Blood Therapeutics Revenue in Hemoglobinopathies Business (2019-2024)
11.5.5 Global Blood Therapeutics Recent Development
11.6 Bluebird Bio
11.6.1 Bluebird Bio Company Detail
11.6.2 Bluebird Bio Business Overview
11.6.3 Bluebird Bio Hemoglobinopathies Introduction
11.6.4 Bluebird Bio Revenue in Hemoglobinopathies Business (2019-2024)
11.6.5 Bluebird Bio Recent Development
11.7 Emmaus Life Sciences Inc.
11.7.1 Emmaus Life Sciences Inc. Company Detail
11.7.2 Emmaus Life Sciences Inc. Business Overview
11.7.3 Emmaus Life Sciences Inc. Hemoglobinopathies Introduction
11.7.4 Emmaus Life Sciences Inc. Revenue in Hemoglobinopathies Business (2019-2024)
11.7.5 Emmaus Life Sciences Inc. Recent Development
11.8 Prolong Pharmaceuticals
11.8.1 Prolong Pharmaceuticals Company Detail
11.8.2 Prolong Pharmaceuticals Business Overview
11.8.3 Prolong Pharmaceuticals Hemoglobinopathies Introduction
11.8.4 Prolong Pharmaceuticals Revenue in Hemoglobinopathies Business (2019-2024)
11.8.5 Prolong Pharmaceuticals Recent Development
11.9 Celgene Corporation
11.9.1 Celgene Corporation Company Detail
11.9.2 Celgene Corporation Business Overview
11.9.3 Celgene Corporation Hemoglobinopathies Introduction
11.9.4 Celgene Corporation Revenue in Hemoglobinopathies Business (2019-2024)
11.9.5 Celgene Corporation Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Hemoglobinopathies Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Blood Transfusion
Table 3. Key Players of Iron Chelation Therapy
Table 4. Key Players of Bone Marrow Transplant
Table 5. Key Players of Others
Table 6. Global Hemoglobinopathies Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Hemoglobinopathies Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 8. Global Hemoglobinopathies Market Size by Region (2019-2024) & (US$ Million)
Table 9. Global Hemoglobinopathies Market Share by Region (2019-2024)
Table 10. Global Hemoglobinopathies Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 11. Global Hemoglobinopathies Market Share by Region (2025-2030)
Table 12. Hemoglobinopathies Market Trends
Table 13. Hemoglobinopathies Market Drivers
Table 14. Hemoglobinopathies Market Challenges
Table 15. Hemoglobinopathies Market Restraints
Table 16. Global Hemoglobinopathies Revenue by Players (2019-2024) & (US$ Million)
Table 17. Global Hemoglobinopathies Market Share by Players (2019-2024)
Table 18. Global Top Hemoglobinopathies Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hemoglobinopathies as of 2023)
Table 19. Ranking of Global Top Hemoglobinopathies Companies by Revenue (US$ Million) in 2023
Table 20. Global 5 Largest Players Market Share by Hemoglobinopathies Revenue (CR5 and HHI) & (2019-2024)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Hemoglobinopathies Product Solution and Service
Table 23. Date of Enter into Hemoglobinopathies Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Hemoglobinopathies Market Size by Type (2019-2024) & (US$ Million)
Table 26. Global Hemoglobinopathies Revenue Market Share by Type (2019-2024)
Table 27. Global Hemoglobinopathies Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 28. Global Hemoglobinopathies Revenue Market Share by Type (2025-2030)
Table 29. Global Hemoglobinopathies Market Size by Application (2019-2024) & (US$ Million)
Table 30. Global Hemoglobinopathies Revenue Market Share by Application (2019-2024)
Table 31. Global Hemoglobinopathies Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 32. Global Hemoglobinopathies Revenue Market Share by Application (2025-2030)
Table 33. North America Hemoglobinopathies Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 34. North America Hemoglobinopathies Market Size by Country (2019-2024) & (US$ Million)
Table 35. North America Hemoglobinopathies Market Size by Country (2025-2030) & (US$ Million)
Table 36. Europe Hemoglobinopathies Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 37. Europe Hemoglobinopathies Market Size by Country (2019-2024) & (US$ Million)
Table 38. Europe Hemoglobinopathies Market Size by Country (2025-2030) & (US$ Million)
Table 39. Asia-Pacific Hemoglobinopathies Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 40. Asia-Pacific Hemoglobinopathies Market Size by Region (2019-2024) & (US$ Million)
Table 41. Asia-Pacific Hemoglobinopathies Market Size by Region (2025-2030) & (US$ Million)
Table 42. Latin America Hemoglobinopathies Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 43. Latin America Hemoglobinopathies Market Size by Country (2019-2024) & (US$ Million)
Table 44. Latin America Hemoglobinopathies Market Size by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Hemoglobinopathies Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 46. Middle East & Africa Hemoglobinopathies Market Size by Country (2019-2024) & (US$ Million)
Table 47. Middle East & Africa Hemoglobinopathies Market Size by Country (2025-2030) & (US$ Million)
Table 48. Gamida Cell Company Detail
Table 49. Gamida Cell Business Overview
Table 50. Gamida Cell Hemoglobinopathies Product
Table 51. Gamida Cell Revenue in Hemoglobinopathies Business (2019-2024) & (US$ Million)
Table 52. Gamida Cell Recent Development
Table 53. Alnylam Pharmaceuticals Company Detail
Table 54. Alnylam Pharmaceuticals Business Overview
Table 55. Alnylam Pharmaceuticals Hemoglobinopathies Product
Table 56. Alnylam Pharmaceuticals Revenue in Hemoglobinopathies Business (2019-2024) & (US$ Million)
Table 57. Alnylam Pharmaceuticals Recent Development
Table 58. Sanofi Company Detail
Table 59. Sanofi Business Overview
Table 60. Sanofi Hemoglobinopathies Product
Table 61. Sanofi Revenue in Hemoglobinopathies Business (2019-2024) & (US$ Million)
Table 62. Sanofi Recent Development
Table 63. Sangamo Therapeutics Inc. Company Detail
Table 64. Sangamo Therapeutics Inc. Business Overview
Table 65. Sangamo Therapeutics Inc. Hemoglobinopathies Product
Table 66. Sangamo Therapeutics Inc. Revenue in Hemoglobinopathies Business (2019-2024) & (US$ Million)
Table 67. Sangamo Therapeutics Inc. Recent Development
Table 68. Global Blood Therapeutics Company Detail
Table 69. Global Blood Therapeutics Business Overview
Table 70. Global Blood Therapeutics Hemoglobinopathies Product
Table 71. Global Blood Therapeutics Revenue in Hemoglobinopathies Business (2019-2024) & (US$ Million)
Table 72. Global Blood Therapeutics Recent Development
Table 73. Bluebird Bio Company Detail
Table 74. Bluebird Bio Business Overview
Table 75. Bluebird Bio Hemoglobinopathies Product
Table 76. Bluebird Bio Revenue in Hemoglobinopathies Business (2019-2024) & (US$ Million)
Table 77. Bluebird Bio Recent Development
Table 78. Emmaus Life Sciences Inc. Company Detail
Table 79. Emmaus Life Sciences Inc. Business Overview
Table 80. Emmaus Life Sciences Inc. Hemoglobinopathies Product
Table 81. Emmaus Life Sciences Inc. Revenue in Hemoglobinopathies Business (2019-2024) & (US$ Million)
Table 82. Emmaus Life Sciences Inc. Recent Development
Table 83. Prolong Pharmaceuticals Company Detail
Table 84. Prolong Pharmaceuticals Business Overview
Table 85. Prolong Pharmaceuticals Hemoglobinopathies Product
Table 86. Prolong Pharmaceuticals Revenue in Hemoglobinopathies Business (2019-2024) & (US$ Million)
Table 87. Prolong Pharmaceuticals Recent Development
Table 88. Celgene Corporation Company Detail
Table 89. Celgene Corporation Business Overview
Table 90. Celgene Corporation Hemoglobinopathies Product
Table 91. Celgene Corporation Revenue in Hemoglobinopathies Business (2019-2024) & (US$ Million)
Table 92. Celgene Corporation Recent Development
Table 93. Research Programs/Design for This Report
Table 94. Key Data Information from Secondary Sources
Table 95. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Hemoglobinopathies Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Hemoglobinopathies Market Share by Type: 2023 VS 2030
Figure 3. Blood Transfusion Features
Figure 4. Iron Chelation Therapy Features
Figure 5. Bone Marrow Transplant Features
Figure 6. Others Features
Figure 7. Global Hemoglobinopathies Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 8. Global Hemoglobinopathies Market Share by Application: 2023 VS 2030
Figure 9. Blood Testing Case Studies
Figure 10. Genetic Testing Case Studies
Figure 11. Pre-Implantation Genetic Diagnosis (PGD) Case Studies
Figure 12. Others Case Studies
Figure 13. Hemoglobinopathies Report Years Considered
Figure 14. Global Hemoglobinopathies Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 15. Global Hemoglobinopathies Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 16. Global Hemoglobinopathies Market Share by Region: 2023 VS 2030
Figure 17. Global Hemoglobinopathies Market Share by Players in 2023
Figure 18. Global Top Hemoglobinopathies Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hemoglobinopathies as of 2023)
Figure 19. The Top 10 and 5 Players Market Share by Hemoglobinopathies Revenue in 2023
Figure 20. North America Hemoglobinopathies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. North America Hemoglobinopathies Market Share by Country (2019-2030)
Figure 22. United States Hemoglobinopathies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Canada Hemoglobinopathies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. Europe Hemoglobinopathies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. Europe Hemoglobinopathies Market Share by Country (2019-2030)
Figure 26. Germany Hemoglobinopathies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. France Hemoglobinopathies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. U.K. Hemoglobinopathies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Italy Hemoglobinopathies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Russia Hemoglobinopathies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Nordic Countries Hemoglobinopathies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Asia-Pacific Hemoglobinopathies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Asia-Pacific Hemoglobinopathies Market Share by Region (2019-2030)
Figure 34. China Hemoglobinopathies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Japan Hemoglobinopathies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. South Korea Hemoglobinopathies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Southeast Asia Hemoglobinopathies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. India Hemoglobinopathies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Australia Hemoglobinopathies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Latin America Hemoglobinopathies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Latin America Hemoglobinopathies Market Share by Country (2019-2030)
Figure 42. Mexico Hemoglobinopathies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Brazil Hemoglobinopathies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Middle East & Africa Hemoglobinopathies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Middle East & Africa Hemoglobinopathies Market Share by Country (2019-2030)
Figure 46. Turkey Hemoglobinopathies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Saudi Arabia Hemoglobinopathies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 48. Gamida Cell Revenue Growth Rate in Hemoglobinopathies Business (2019-2024)
Figure 49. Alnylam Pharmaceuticals Revenue Growth Rate in Hemoglobinopathies Business (2019-2024)
Figure 50. Sanofi Revenue Growth Rate in Hemoglobinopathies Business (2019-2024)
Figure 51. Sangamo Therapeutics Inc. Revenue Growth Rate in Hemoglobinopathies Business (2019-2024)
Figure 52. Global Blood Therapeutics Revenue Growth Rate in Hemoglobinopathies Business (2019-2024)
Figure 53. Bluebird Bio Revenue Growth Rate in Hemoglobinopathies Business (2019-2024)
Figure 54. Emmaus Life Sciences Inc. Revenue Growth Rate in Hemoglobinopathies Business (2019-2024)
Figure 55. Prolong Pharmaceuticals Revenue Growth Rate in Hemoglobinopathies Business (2019-2024)
Figure 56. Celgene Corporation Revenue Growth Rate in Hemoglobinopathies Business (2019-2024)
Figure 57. Bottom-up and Top-down Approaches for This Report
Figure 58. Data Triangulation
Figure 59. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
